For research use only
| Cat No. | ABC-TC5590 |
| Product Type | Human Ovarian Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Disease | Ovarian Cancer |
| Product Code | PE01; PEO-1; PEO |
PEO1 ovarian adenocarcinoma cells show near-triploid karyotype, BRCA2 mutation, express CA125 and EpCAM, tumorigenic, used for ovarian cancer research.
PEO1 is a human ovarian adenocarcinoma cell line that was derived from patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages. PEO1 exhibits epithelial-like morphology, islands of uniform polygonal cells and adherent culture properties. The stemline analysis of PEO1 shows it has complex aneuploid karyotype with chromosomal counts in the near-triploid range. PEO1 carrying a homozygous BRCA2 mutation (c. 5193C>G) which indicate to impaired DNA repair capacity. This cell line test positive for CA125 and EpCAM and low expression of estrogen receptor (ER) and progesterone receptor (PR). PEO1 is tumorigenic in SCID mice, making it a robust in vivo model for translational cancer research.
| Product Code | PE01; PEO-1; PEO |
| Species | Human |
| Cat.No | ABC-TC5590 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Disease | Ovarian Cancer |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
PEO1 cell line is a critical resource in oncology and pharmacology research. Within the cancer field, it offers insights into the mechanism of estrogen action on ovarian adenocarcinoma tumor cells. Additionally, PEO1 is valuable for investigating the role of estrogen signaling in ovarian tumor progression and for assessing the efficacy and cytotoxicity of estrogen agonists or antagonists. Its relevance to drug resistance modeling, targeted therapy screening, and tumor biology makes it indispensable in the development of novel therapeutic strategies for ovarian adenocarcinoma.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
